The diagnostic value of a new formula combining age and prostate volume in prostate cancer

• Published in: Journal of Men's Health Vol. 18; no. 2; p. 29
• Main Authors: Yang, Xiaobo, Shan, Jiahao, Zhang, Qiang, Yuan, Zhongyu, Xu, Haoran, Liu, Ziyang, Zhou, Xiaojie, Ma, Wenzhuo, Shi, Hongbin
• Format: Journal Article
• Language: English
• Published: MRE Press 01.02.2022
• Subjects: prostate cancer; prostate-specific antigen; prostate-specific antigen density; psa-av score
• ISSN: 1875-6867; 1875-6859
• DOI: 10.31083/jomh.2021.080

Background and objective: This study combined two clinical indicators (age and prostate volume (PV)) to generate age to PV (AVR) ratio, whose diagnostic value for prostate cancer (PCa) was examined based on prostate specific antigen (PSA) in the range of 4–20.0 ng/mL. Methods: The medical records of patients who underwent transrectal ultrasound-guided biopsy of the prostate in our hospital from June 2015 to June 2019 were examined retrospectively. According to the pathological results of the biopsy, the patients were divided into the PCa and benign prostatic hyperplasia (BPH) groups. Receiver operating characteristic (ROC) curves for TPSA, PSAD, PV, (F/T)PSA, AVR, and PSA-AV were plotted with SPSS 26.0 and GraphPad Prism 5.0, and areas under the ROC curves (AUROCs) were determined and compared by Delong test. A log-linear model was used to compare AVR and other parameters with similar high sensitivities, for specificity. Results: The AUROC for AVR was significantly different from those of TPSA (p < 0.001), PV (p = 0.004), (F/T)PSA (p < 0.001), and PSA-AV (p = 0.006), and similar to that of PSAD (p = 0.064). With the same high sensitivity (90.0%), log-linear model analysis showed that the specificity of AVR was significantly higher than those of TPSA and (F/T)PSA (p < 0.01), while there were no significant differences among AVR and PSAD, PV and PSA-AV. Conclusion: With PSA in the range of 4–20.0 ng/mL, AVR may be useful in sparing an invasive intervention for a number of patients.